更新于：2024-11-01

Lewis B抗原

更新于：2024-11-01

基本信息

别名-

简介-

关联

项与 Lewis B抗原相关的药物

RebmAb300

靶点

Lewis B抗原

作用机制

Lewis B抗原抑制剂

在研机构

Recepta Biopharma SA

原研机构

Recepta Biopharma SA

在研适应症

恶性上皮肿瘤

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期1800-01-20

58-1066 mAb

靶点

Lewis B抗原

作用机制

Lewis B抗原抑制剂

在研机构

Recepta Biopharma SA

原研机构

Ludwig Institute for Cancer Research Ltd.

在研适应症

肿瘤

非在研适应症-

最高研发阶段药物发现

首次获批国家/地区-

首次获批日期1800-01-20

100 项与 Lewis B抗原相关的临床结果

登录后查看更多信息

100 项与 Lewis B抗原相关的转化医学

登录后查看更多信息

0 项与 Lewis B抗原相关的专利（医药）

登录后查看更多信息

378

项与 Lewis B抗原相关的文献（医药）

2025-01-01·Clinica Chimica Acta

Carbohydrate antigens Lewis a and Lewis b act as tumor markers cooperating with CA19.9 in the management of PDAC patients

Article

作者: Indellicato, Rossella ; Tosi, Delfina ; Bulfamante, Gaetano ; Pistillo, Daniela ; Caretti, Anna ; Zerbi, Alessandro ; Dei Cas, Michele ; Zulueta, Aida ; Scifo, Giovanna ; Opocher, Enrico ; Nappo, Gennaro ; Cigala, Claudia ; De Nicola, Enrico ; Trinchera, Marco

BACKGROUNDCA19.9 is the unique marker recommended for the preoperative staging and the follow-up of patients suffering from pancreatic ductal adenocarcinoma (PDAC) but up to 30% of PDAC patients maintain normal CA19.9 values and cannot be monitored in this way. Lewis a (Lea Galβ1,3[Fucα1,4]GlcNAc) and b (Leb, Fucα1,2Galβ1,3[Fucα1,4]GlcNAc) are antigens which are structurally similar to sialyl-Lewis a (Siaα2,3Galβ1,3[Fucα1,4]GlcNAc), the epitope of CA19.9.METHODSWe set an ELISA procedure determining the levels of Lea, Leb, and CA19.9 in the blood of healthy individuals or PDAC patients. Moreover, such antigens were also detected in cancer resections by immunofluorescence microscopy, and the levels of glycosyltransferase transcripts involved in Lewis antigen biosynthesis were determined by RT-qPCR.RESULTSIn our cohort of 116 healthy individuals, the distribution of circulating Lea and Leb was similar to that of CA19.9, allowing us to set putative cutoff values for both antigens. In a cohort of 115 PDAC patients, the differential distribution with respect to the controls was statistically significant for both antigens (p < 0.001). Out of 37 patients presenting normal CA19.9 values, 15 patients presented Lea or Leb above the cutoffs. By immunofluorescence, Lea, Leb and CA19.9 were all detected in cancer resections and expression levels were heterogeneous among patients in terms of intensity, localization and diffusion. The levels of relevant glycosyltransferase transcripts were found to be heterogeneous between cancers of different patients and no association was detectable with the levels of any circulating antigen.CONCLUSIONSThe concurrent quantification of Lea and Leb together with CA19.9 improves the management of PDAC patients.

2024-07-13·Cureus

Lewis-A Antibody in Clinical Practice: A Case Report

Article

作者: I, Suresh K ; V, Soundharya ; R, Arthi ; James, Sahayaraj ; Haran A, Hari

Anti-Lewis antibodies are often not clinically significant since they do not react at 37°C. These antibodies have, however, occasionally been linked to hemolytic transfusion reactions (HTR). We report a case of naturally occurring anti-Lewis-a (Le-a) in a 58-year-old patient found during routine blood grouping. As Lewis antigen is a low-prevalence antigen, compatible units were found after crossmatching two units of packed red cells. Lewis blood group antigen antibodies frequently react at lower temperatures and remain clinically insignificant, but in rare cases, they may react at a higher temperature of 37°C and cause a hemolytic episode or impair the lifespan of incompatible red blood cells in the recipient. Hence, antigen-negative crossmatch compatible units should be used for transfusion. In an emergency, the donor's register, with its comprehensive phenotypic profile, can be quite helpful in supplying blood for transfusions.

2024-07-13·Cureus

Lewis-A Antibody in Clinical Practice: A Case Report

Article

作者: Haran A, Hari ; I, Suresh K ; V, Soundharya ; R, Arthi ; James, Sahayaraj